LANZOLLA, Giulia
 Distribuzione geografica
Continente #
EU - Europa 1.883
AS - Asia 1.017
NA - Nord America 834
SA - Sud America 249
AF - Africa 39
OC - Oceania 20
Totale 4.042
Nazione #
IT - Italia 1.639
US - Stati Uniti d'America 794
SG - Singapore 345
CN - Cina 322
BR - Brasile 173
VN - Vietnam 146
NL - Olanda 63
FI - Finlandia 50
HK - Hong Kong 42
IN - India 29
FR - Francia 27
SE - Svezia 26
AR - Argentina 23
ID - Indonesia 23
CA - Canada 20
AU - Australia 19
KR - Corea 19
MX - Messico 19
GB - Regno Unito 17
BD - Bangladesh 15
DE - Germania 15
PE - Perù 15
EC - Ecuador 12
PL - Polonia 12
CO - Colombia 9
TR - Turchia 9
ZA - Sudafrica 9
DZ - Algeria 8
JO - Giordania 8
JP - Giappone 8
MA - Marocco 8
AT - Austria 7
TH - Thailandia 7
CL - Cile 6
IE - Irlanda 6
MY - Malesia 6
IQ - Iraq 5
UA - Ucraina 5
KE - Kenya 4
VE - Venezuela 4
IR - Iran 3
PK - Pakistan 3
PT - Portogallo 3
PY - Paraguay 3
RU - Federazione Russa 3
SA - Arabia Saudita 3
BO - Bolivia 2
EG - Egitto 2
ES - Italia 2
IL - Israele 2
KW - Kuwait 2
OM - Oman 2
PH - Filippine 2
TN - Tunisia 2
UY - Uruguay 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
HR - Croazia 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
SB - Salomone, isole 1
SD - Sudan 1
TW - Taiwan 1
Totale 4.042
Città #
Cagliari 1.505
Singapore 211
Dallas 208
San Jose 111
Ashburn 86
Beijing 60
Ho Chi Minh City 56
Hefei 51
Los Angeles 46
Hanoi 39
Chicago 38
Helsinki 37
Hong Kong 35
Council Bluffs 29
São Paulo 24
Amsterdam 23
Seoul 19
Lauterbourg 18
Heumen 16
Salt Lake City 16
New York 15
Guangzhou 14
Hengelo 14
Orem 14
Redondo Beach 13
Buffalo 12
Lappeenranta 12
Mexico City 12
Montreal 12
Rome 12
Tortolì 12
Warsaw 11
Melbourne 9
Rende 9
Rio de Janeiro 9
Santa Clara 9
Xi'an 9
Chennai 8
Amman 7
Boardman 7
Da Nang 7
Jakarta 7
Lima 7
Maize 7
Selargius 7
Dublin 6
Frankfurt am Main 6
Casalecchio di Reno 5
Elk Grove Village 5
Johannesburg 5
Nuremberg 5
Shenzhen 5
Algiers 4
Bangkok 4
Brasília 4
Buenos Aires 4
Guayaquil 4
Hyderabad 4
Manchester 4
Miami 4
Santiago 4
Shenyang 4
Stockholm 4
Sydney 4
Tampa 4
Uta 4
Vienna 4
Agliana 3
Ankara 3
Atlanta 3
Baghdad 3
Belo Horizonte 3
Biên Hòa 3
Boston 3
Brisbane 3
Brooklyn 3
Cape Town 3
Changzhou 3
Dhaka 3
Dulles 3
Kansas City 3
Lancaster 3
Logan 3
Louisa 3
Lviv 3
Milan 3
Nanjing 3
New Delhi 3
Pavia 3
Phoenix 3
Poplar 3
Porto 3
Pune 3
Quito 3
Ribeirão Preto 3
Rio das Ostras 3
Salvador 3
Shanghai 3
The Dalles 3
Tianjin 3
Totale 3.079
Nome #
Graves disease: latest understanding of pathogenesis and treatment options 431
Oxidative phosphorylation in bone cells 418
Risk of Neck Hematoma Following Thyroidectomy in Patients Taking Direct Oral Anticoagulants: A Propensity Score Matching Analysis from Nine High-Volume European Centers (RAGNO Study) 216
Editorial: News in Graves’ orbitopathy: patients management and treatments 205
Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III) 151
Detection of Central Compartment Lymph Node Metastasis of Thyroid Cancer: Usefulness of Intraoperative Thyroglobulin Measurement in Fine Needle Aspiration Washout with and Without Blue Dye Injection 136
Graves’ Disease: Is It Time for Targeted Therapy? A Narrative Review 132
Long-term outcome of Graves’ orbitopathy following treatment with sirolimus 132
HIF1 activation safeguards cortical bone formation against impaired oxidative phosphorylation 131
Osteoblastic erythropoietin is not required for bone mass accrual 131
Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy 122
Ocular surface disease index in Graves’ orbitopathy: a cross-sectional study 115
Pharmacological inhibition of HIF2 protects against bone loss in an experimental model of estrogen deficiency 103
Sirolimus as a second-line treatment for Graves’ orbitopathy 93
Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women 89
Selenium in the Treatment of Graves’ Hyperthyroidism and Eye Disease 87
Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy 85
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-l1 blockade: Insights from four cases 80
Disappearance of Anti-Thyroid Autoantibodies following Thymectomy in Patients with Myasthenia Gravis 72
IgG4 serum levels in Graves’ orbitopathy 71
Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves’ Orbitopathy: A Retrospective Cohort Study 69
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment 68
Antioxidant Therapy in Graves’ Orbitopathy 67
Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study 65
Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study 58
In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ orbitopathy 57
Absence of a relationship between vitamin D and Graves’ orbitopathy 51
Erythropoietin and skeletal cells crosstalks in physiology and disease 46
Insights into the Role of DNA Methylation and Gene Expression in Graves Orbitopathy 44
null 39
Androgens and Hypertension in Men and Women: a Unifying View 35
Statins in Graves Orbitopathy: A New Therapeutic Tool 32
Immune checkpoint blockade Anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome 32
Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy 32
Oxidative Stress in Graves Disease and Graves Orbitopathy 31
Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis 29
Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk 28
Genetic Profiling of Orbital Fibroblasts from Patients with Graves' Orbitopathy 28
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy 26
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial 26
Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ Disease: results of a pilot study 25
Graves’ disease and Graves’ orbitopathy following COVID-19 24
Occurrence of Graves’ hyperthyroidism and Graves’ orbitopathy after fine-needle aspiration biopsy of thyroid nodules 23
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy 22
Statins: A New Hope on the Horizon of Graves Orbitopathy? 22
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study 21
The Glu331del mutation in the CYP17A1 gene causes atypical congenital adrenal hyperplasia in a 46,XX female 19
Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocols 19
null 16
null 13
null 12
null 12
null 12
null 10
null 10
null 9
null 8
null 7
null 7
null 7
null 7
null 7
null 7
Totale 4.182
Categoria #
all - tutte 7.278
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.278


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.165 0 0 0 0 411 86 100 11 8 13 265 271
2025/20263.017 164 240 433 308 215 160 264 544 267 414 8 0
Totale 4.182